Disclosed herein are therapeutic polymer gel systems for promoting healing of a wound or surgical site in a subject. The therapeutic polymer gel forms a microporous network and may be applied or injected in a fluid form and annealed or crosslinked after application to the wound or surgical site. The microporous gel may optionally contain various therapeutic agents throughout the therapeutic polymer gel which are released.

This invention reveals the potential applications of modified porcine plasma fibronectin that could be applied as a safe material for clinical wound healing and tissue repair. In order to seek safe sources of plasma fibronectin for practical consideration in wound dressing, this invention isolated and modified fibronectin from porcine plasma and demonstrated that modified porcine plasma fibronectin has similar ability as homo plasma fibronectin being as a suitable substrate for stimulation of cell adhesion and directed cell migration. The present invention also reveals a material and a pharmaceutical composition enhance wound healing.

Glucocorticoid-induced leucine zipper protein (GILZ) peptide compositions and their methods of use in wound healing are disclosed herein. An exemplary GILZ peptide composition includes a GILZ fusion protein. The GILZ peptide compositions can be administered topically to wounds, for example in the form of a cream, ointment, or lotion. The GILZ peptide compositions can be used to treat acute wounds, induce wound healing in chronic wounds, and reduce scar formation.

A set of cationic amphiphilic self-assembled peptides (CASPs) is presented that employ high-charge density at fiber edges to disrupt bacterial membranes. CASP nanofibers are effective against Pseudomonas biofilms. There is an inherent trade-off between the ability of the peptides to undergo nanofibrous self-assembly and having a high terminal charge density required for effective bactericidal efficacy. The self-assembled peptide hydrogel presented achieves a balance of these opposing factors. Also demonstrated is the applicability of the new composition in an injectable hydrogel formulation. A CASP platform may be useful for topical application and integration into medical coatings, grafts, devices, and prostheses, thereby reducing risk of bacterial infection and related failure.

A hemostatic product that includes a dry fibrinogen mixture, a dry thrombin mixture and a biologically tolerable liquid. The dry fibrinogen mixture includes fibrinogen and at least one fibrinogen stabilizer. The dry thrombin mixture includes thrombin and at least one thrombin stabilizer. The biologically tolerable liquid is mixed with the dry fibrinogen mixture and the dry thrombin mixture to form the hemostatic product.

Disclosed by the present invention are a medical device, hydrogel, preparation method therefor, and use thereof. The hydrogel is formed by polymerization reaction of antibacterial polypeptide and a buffer solution, the antibacterial polypeptide being polypeptide or a polypeptide derivative thereof represented by the following amino acid sequence: Pro-Phe-Lys-Leu-Ser-Leu-His-Leu-NH.sub.2. The hydrogel of the present invention has self-healing properties, and can be injectable and degraded in vivo and in vitro, needs moderate time for complete degradation, and is degraded after the drug effect is fully achieved; the hydrogel has a remarkable inhibiting effect on growth and proliferation of bacteria and fungi, has antibacterial and anti-inflammatory activity and excellent hemostatic properties, and has the advantages such as small cytotoxicity, substantially expressing no hemolytic activity, and excellent biocompatibility; and the hydrogel according to the present invention is excellent in anti-adhesion activity, does not adhere to wounds, is quickly crosslinked at 37 C., has a excellent effect of preventing postoperative adhesion and has obvious advantages in clinical practice.

A method for preparing a composition for external treatment of wounds includes charging at least 90% of the oxygen binding sites of hemoglobin with carbon monoxide during or after isolation from its natural environment. The method further includes adding at least one further ingredient selected from the group consisting of electrolyte(s), preservative(s), stabilizer(s), anti-flocculant(s), anticoagulant(s), pH buffering agent(s), solvent(s), antioxidant(s), film-forming agent(s) and crosslinking agent(s). The method can further include packaging the composition, such as in an aerosol can.

One aspect of the invention provides a method of treating a chronic wound including administering to the wound at least one agent from a delivery system wherein the agent induces sequential conversion of a first population of wound macrophages in the wound to M2A macrophages and a second population of wound macrophages to M2C macrophages. The sequential conversion of the wound macrophages promotes tissue remodeling.

To provide a liquid medical material maintaining a colloid in a more sol form than a solid at normal temperature, having a higher function as a wound dressing material and a hemostatic material than fibrin glue, and being able to be produced safely and inexpensively. A gelatin aqueous solution including calcium at a concentration of 0.2 M or more and 1.0 M or less, and having a concentration of 5% by weight or more and 40% by weight or less, an average molecular weight of 80,000 or more and 120,000 or less, and a molecular weight distribution of 20,000 or more and 300,000 or less, and transglutaminase inducing crosslinking of the gelatin, are included. It is preferable that the calcium has a concentration of 0.2 M or more and 0.7 M or less, the gelatin has a bloom of 160 or more and 250 or less, and the transglutaminase has activity per unit of 36 U/ml to 400 U/ml.

A method of treating radiation-induced skin toxicity or skin ulcers with nanoparticles after exposure to ionizing radiation and after an onset of radiation-induced skin toxicity or a radiation-induced skin ulcer by administering intravenously a suspension including fibrinogen-coated albumin nanospheres to a patient. A concentration of the suspension being sufficient to at least one of promote healing of the skin toxicity or reduce a size of the skin ulcer. The suspension can include fibrinogen-coated albumin nanospheres, sorbitol and/or caprylate. The suspension can be utilized for treating a patient to reduce an amount of blood loss in an organ of the patient or for treating a patient to mobilize stem cells or progenitor cells to accelerate healing of a wound.